Member Info for Fredd1eboy

Good morning David.....The question was asked and answered....Funding is in place ensuring there will be no more need for any placings in the foreseeable future.

. . Great to have Adam assisting steering the company, as his vetinary skills should not to be ignored......A top of the league Gent along with Arron.

Mindfull of the diversity of applications, I'm trusting that this RNS is a precursor to a regular stream of value added news, Onwards and upwards my friends

Too true GG

Spot on, as usual ant.....your positivity throughout the past months has been both rewarding and really appreciated. Let's see if the investment market start looking further than the end of its nose. Fingers crossed my friend

Great news BB.....Let's hope that the investment community start looking at the scope and variety of Apt applications to appreciate this little gem of a company which is clearly destined for greatness.

Successful project delivery of Optimer binders with proven function as vaccine adjuvants

Aptamer to receive 10% royalties on downstream sales of any Optimer-containing vaccines

Great news!

Looking better every day mate.....fingers crossed.

Story of my life ant .....any efforts changing the order BOOK upwards alias Boodle....appreciated....Thanks team. Best regards Fred

I'd buy but now bloke....anyone going for it?

Hi BB....We have it from the horses mouth that funding will NOT be an issue.....my guess is the market is just slowing awaiting £££'s value added indisputable data. .. Also as ant mentioned....the last months of a directors salary to be paid in shares.....So exciting value added times in the cross wires.

RNAi.....An option??

Many thanks for the reminder ant.....Sincerely Fred

Due to the nature and diversity of Aptamer use...I'd never be surprised if the technology is moved forward at a regulatory pace.....Great to know the States is yet again the platform for peer update.

NEW possibilities for effective, tissue-specific gene therapies across a wide range of chronic diseases.

Agreed NOK.....Hopefully the subject of this RNS will stimulate even more investor interest together the contents of his presentation giving hope to so many suffering this awful disease.

Dr David Bunka, Aptamer's Chief Scientific Officer, will present the latest advances regarding Aptamer's proprietary Optimer® delivery vehicle, demonstrating its precision-targeting capabilities for FIBROTIC LIVER DISEASE-

Https://www.lse.co.uk/rns/APTA/aptamer-presenting-at-asgct-annual-meeting-jhbf4242tkxlgxl.html

Https://www.linkedin.com/posts/the-aptamer-group_its-national-deodorant-day-a-day-to-celebrate-activity-7322643307879165954-9qTq?utm_source=social_share_send&utm_medium=android_app&rcm=ACoAAAx41aAB-s-GG7MzyP5t-m_sVg2s5QnfYRI&utm_campaign=copy_link